title: [Pharmacokinetics of aztreonam on hemodialysis].
abstract: We studied the pharmacokinetics of aztreonam (AZT) in 6 patients with renal insufficiencies during nonhemodialysis and hemodialysis. After intravenous injection of 1 g AZT, it was found that serum AZT concentrations during hemodialysis were different from those during nonhemodialysis and serum half-lives (T 1/2 beta) were 3.44 hours and 16.97 hours, respectively. AZT clearance changed from 0.762 L/hr during hemodialysis to 3.360 L/hr during nonhemodialysis. These findings suggest that hemodialysis patients should receive the standard dose of AZT as a loading dose, followed by one-half the loading dose per day and receive a supplemental dose equal to half their usual maintenance dose after each dialysis session.
authors.affiliation: Dialysis Unit, Hyogo College of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Nagasaka
authors.forename: O
authors.initials: O
authors.lastname: Inagaki
authors.forename: M
authors.initials: M
authors.lastname: Nasu
authors.forename: K
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nishian
authors.forename: K
authors.initials: K
authors.lastname: Hiraoka
authors.forename: T
authors.initials: T
authors.lastname: Syono
authors.forename: M
authors.initials: M
authors.lastname: Azuma
authors.forename: T
authors.initials: T
authors.lastname: Hirabayashi
authors.forename: H
authors.initials: H
authors.lastname: Mori
mesh_terms: D000368:Aged; D001398:Aztreonam / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011485:Protein Binding; D006435:Renal Dialysis
chemical_list: D001398:Aztreonam